Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392834 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
A Phase 2 study of Lymphoma, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 13
- Study locations
NCT00392834 is a Phase 2 study of Lymphoma that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 34 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 9 states.
The verdict
NCT00392834, a Phase 2 study of Lymphoma, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 13
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed, HIV-associated Burkitt's lymphoma.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- BIOLOGICAL filgrastim
- DRUG cytarabine
- BIOLOGICAL pegfilgrastim
Study Locations (13)
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- UCLA Clinical AIDS Research and Education (CARE) Center - Los Angeles
- UCSF Medical Center at Parnassus - San Francisco
New York
- Memorial Sloan-Kettering Cancer Center - New York
- Albert Einstein Cancer Center at Albert Einstein College of Medicine - The Bronx
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Missouri
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis - St Louis
Ohio
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center - Columbus
Pennsylvania
- Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia - Philadelphia
Washington
- Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392834
The ClinicalTrials.gov registry entry for NCT00392834 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00392834 reports 13 study locations spanning 9 distinct geographic areas - top geographies include California, New York, Maryland.
Frequently Asked Questions
What is clinical trial NCT00392834 about?
NCT00392834 is a clinical study titled "Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma". RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop...
What is the current status of trial NCT00392834?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2006-09. Estimated completion is 2013-07.
What conditions does trial NCT00392834 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00392834?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), filgrastim (BIOLOGICAL), cytarabine (DRUG), pegfilgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00392834?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00392834 being conducted?
This trial has 13 study locations across California, Maryland, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.